Interní Med. 2006; 8(11): 499-501

Multidisciplinary approach in the managent of the patients with the cardiorenal failure - first experience

MUDr. Filip Málek1, MUDr. Martin Havrda2
1 Kardiocentrum FN Královské Vinohrady, III. lékařská fakulta Univerzity Karlovy, Praha
2 I. interní klinika FN Královské Vinohrady 3. LF UK, Praha

Renal impairment is identified in the patients with chronic heart failure more often than in general population and than in the subjects with heart disease and preserved left ventricular function. Presence of chronic kidney disease is also an important risk factor of death in the patients with heart failure. Co-existence of heart failure and renal impairment has a bad prognosis. Some authors name this connection as a cardiorenal syndrome. Management of the patients with both heart failure and renal impairment requires the multidisciplinary approach based on the co-operation of cardiologist-heart failure specialist and nefrologist. Preliminary data from the specialized tertiary care outpatient clinic show, that this approach based on an agressive medical therapy is in the patients with severe cardiorenal syndrome associated with the clinical and haemodynamic improvement without significant decrease in the kidney function during short term follow-up.

Keywords: Key words: chronic kidney disease, chronic heart failure, specialized out-patient clonic.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F, Havrda M. Multidisciplinary approach in the managent of the patients with the cardiorenal failure - first experience. Interní Med. 2006;8(11):499-501.
Download citation

References

  1. The Acute Infarction Ramipril Efficacy(AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828. Go to original source...
  2. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002 Apr 3; 39 (7): 1113-1119. Go to original source... Go to PubMed...
  3. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome:, ,Guyton revisited". Eur Heart J 2005 Jan; 26 (1): 11-17. Go to original source... Go to PubMed...
  4. Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection. Hypertension 2004 Apr; 43 (4): e14. Go to original source... Go to PubMed...
  5. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357: 1385-1390. Go to original source... Go to PubMed...
  6. CIBIS Investigators and Commities. The Cardiac Insufficiency Bisoprolol Study II. (CIBIS II). Lancet, 1999, 353: 9-13. Go to original source...
  7. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16: 31-41. Go to original source... Go to PubMed...
  8. Cohen N, Gorelik O, Almoznino-Sarafian D, Alon I, Tourovski Y, Weissgarten J, Chachashvily S, Shteinshnaider M, Modai D. Renal dysfunction in congestive heart failure, pathophysiological and prognostic significance. Clin Nephrol 2004 Mar; 61 (3): 177-184. Go to original source... Go to PubMed...
  9. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-1435.
  10. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987 Jun; 31 (6): 1402-1415. Go to original source... Go to PubMed...
  11. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998, 9, (Suppl. 12): S16-S23. Go to original source... Go to PubMed...
  12. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003 Apr 16; 41 (8): 1364-1372. Go to original source... Go to PubMed...
  13. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E, TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003 Nov 5; 42 (9): 1535-1543. Go to original source... Go to PubMed...
  14. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002 Oct; 62 (4): 1402-1407. Go to original source... Go to PubMed...
  15. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D, CATS Randomized Trial. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 2003 Mar; 24 (5): 412-420. Go to original source... Go to PubMed...
  16. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000 Jul 11; 102 (2): 203-210. Go to original source... Go to PubMed...
  17. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. JACC 1993, 22: 6A-13A. Go to original source... Go to PubMed...
  18. Málek F, Špaček R. Blokáda receptoru aldosteronu v terapii chronického srdečního selhání. Cor Vasa 2002, 44 (1): 32-36.
  19. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004 Mar 2; 109 (8): 1004-1009. Go to original source... Go to PubMed...
  20. MERIT-HF Study Group. Effect of Metoprolol CR/XL in Chronic Heart Failure. Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999, 353: 2001-2007. Go to original source...
  21. Packer M, Bristow MR, Cohn JN, et al. For the Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 1996, 334: 1349-1355. Go to original source... Go to PubMed...
  22. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344: 1651-1658. Go to original source... Go to PubMed...
  23. Pfeffer MA, Braunwald E, Moye LA, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669-677. Go to original source... Go to PubMed...
  24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wites J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 753-755. Go to original source... Go to PubMed...
  25. Rao V, Weisel RD, Buth KJ, Cohen G, Borger MA, Shiono N, Bhatnagar G, Fremes SE, Goldman BS, Christakis GT. Coronary artery bypass grafting in patients with non-dialysis-dependent renal insufficiency. Circulation 1997 Nov 4; 96 (9 Suppl): II-38-43; discussion II-44-45.
  26. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302. Go to original source... Go to PubMed...
  27. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003 Jun; 41 (5 Suppl): 11-17. Go to original source... Go to PubMed...
  28. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003 Oct 28; 108 (17): 2154-2169. Go to original source... Go to PubMed...
  29. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrom Circulation 2004, 110: 1514-1517. Go to original source... Go to PubMed...
  30. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003, 138: 917-924. Go to original source... Go to PubMed...
  31. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004 Aug; 10 (4): 297-303. Go to original source... Go to PubMed...
  32. Thorp-Pedersen C,Kober L,Carlsen J. Angiotensin-converting enzyme inhibition after myocardial infarction:the Trandolapril Cardiac Evaluation study. Am Heart J 1996; 132: 235-243. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.